- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Crohn disease. Ulcerative colitis. Active juvenile idiopathic arthritis. Complex refractory fistulising Crohn disease. Active rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis. Chronic plaque psoriasis. Hidradenitis suppurativa
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Adalimumab – March 2026
Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled pen, ,
Last updated
11 March 2026
